DE69835949D1 - Verfahren um immunkoagulation zu modulieren - Google Patents

Verfahren um immunkoagulation zu modulieren

Info

Publication number
DE69835949D1
DE69835949D1 DE69835949T DE69835949T DE69835949D1 DE 69835949 D1 DE69835949 D1 DE 69835949D1 DE 69835949 T DE69835949 T DE 69835949T DE 69835949 T DE69835949 T DE 69835949T DE 69835949 D1 DE69835949 D1 DE 69835949D1
Authority
DE
Germany
Prior art keywords
fgl2
immunoagulation
modulating
immune coagulation
allograft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835949T
Other languages
English (en)
Inventor
Gary Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trillium Therapeutics ULC
Original Assignee
Trillium Therapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trillium Therapeutics ULC filed Critical Trillium Therapeutics ULC
Application granted granted Critical
Publication of DE69835949D1 publication Critical patent/DE69835949D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
DE69835949T 1997-05-15 1998-05-15 Verfahren um immunkoagulation zu modulieren Expired - Lifetime DE69835949D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4653797P 1997-05-15 1997-05-15
US6168497P 1997-10-10 1997-10-10
PCT/CA1998/000475 WO1998051335A1 (en) 1997-05-15 1998-05-15 Methods of modulating immune coagulation

Publications (1)

Publication Number Publication Date
DE69835949D1 true DE69835949D1 (de) 2006-11-02

Family

ID=26724041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835949T Expired - Lifetime DE69835949D1 (de) 1997-05-15 1998-05-15 Verfahren um immunkoagulation zu modulieren

Country Status (8)

Country Link
US (5) US6403089B1 (de)
EP (1) EP0975361B1 (de)
JP (1) JP4499839B2 (de)
AT (1) ATE339964T1 (de)
AU (1) AU742076B2 (de)
CA (1) CA2289979C (de)
DE (1) DE69835949D1 (de)
WO (1) WO1998051335A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69835949D1 (de) * 1997-05-15 2006-11-02 Trillium Therapeutics Inc Verfahren um immunkoagulation zu modulieren
US20050175994A1 (en) * 1999-01-20 2005-08-11 Haley-Vicente Dana A. Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
US6586390B1 (en) 2000-01-21 2003-07-01 Hyseq, Inc. Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides
CA2345478A1 (en) * 2000-11-29 2002-05-29 University Of Guelph Uterine natural killer cells
WO2003027264A2 (en) * 2001-09-27 2003-04-03 University Of Delaware Coisogenic eukaryotic cell collections
US20060078550A1 (en) * 2002-02-07 2006-04-13 Gary Levy Porcine fgl2
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) * 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2477312C (en) * 2002-03-01 2013-02-26 Trillium Therapeutics Inc. Use of soluble fgl2 as an immunosuppressant
DE10309368A1 (de) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase
CA2682429A1 (en) * 2009-05-20 2010-11-20 Gary Levy An assay for measuring plasma fgl-2 and methods and uses thereof
WO2012007940A1 (en) 2010-07-14 2012-01-19 Mor Research Applications Ltd. Fgl-2 prothrombinase as a diagnostic tool for malignancy
US9005630B2 (en) 2012-11-01 2015-04-14 Veterinaerinstituttet Fusion proteins for the treatment of allergic diseases
WO2015143343A2 (en) * 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
WO2016197358A1 (zh) * 2015-06-11 2016-12-15 深圳市第二人民医院 CRISPR-Cas9特异性敲除猪FGL2基因的方法及用于特异性靶向FGL2基因的sgRNA
CN110831622B (zh) * 2017-05-05 2023-06-20 德克萨斯大学系统董事会 Fgl2单克隆抗体及其在治疗恶性肿瘤中的用途
WO2020097236A1 (en) * 2018-11-06 2020-05-14 Board Of Regents, The University Of Texas System Fgl2 neutraling cell therapy and methods of use thereof
WO2021199046A1 (en) * 2020-03-31 2021-10-07 Biond Biologics Ltd. Immunomodulatory compositions and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
US5529934A (en) * 1991-07-29 1996-06-25 Biomide Investment Limited Partnership Method for measuring blood procoagulant activity of human leukocyte antigens
JP3337488B2 (ja) * 1992-03-06 2002-10-21 アベンティス ファーマ株式会社 切迫流産治療剤
DE69835949D1 (de) * 1997-05-15 2006-11-02 Trillium Therapeutics Inc Verfahren um immunkoagulation zu modulieren

Also Published As

Publication number Publication date
US6805863B2 (en) 2004-10-19
JP2001513822A (ja) 2001-09-04
US20050169913A1 (en) 2005-08-04
ATE339964T1 (de) 2006-10-15
US6403089B1 (en) 2002-06-11
CA2289979A1 (en) 1998-11-19
AU742076B2 (en) 2001-12-13
US20030099654A1 (en) 2003-05-29
CA2289979C (en) 2007-02-20
EP0975361A1 (de) 2000-02-02
US20030103974A1 (en) 2003-06-05
WO1998051335A1 (en) 1998-11-19
AU7421398A (en) 1998-12-08
JP4499839B2 (ja) 2010-07-07
EP0975361B1 (de) 2006-09-20
US20070128198A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
ATE339964T1 (de) Verfahren um immunkoagulation zu modulieren
DE3382530D1 (de) Verfahren zur behandlung von ueberweisungen.
DE69010893T2 (de) Verfahren zur behandlung von koks sowie löschen desselben.
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
DK0528858T3 (da) Inhibitorer af dipeptidyl-aminopeptidase type IV
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
DE3877834T2 (de) Verfahren zur behandlung von abgasen.
DE69833779D1 (de) Verfahren und zusammensetzungen zur immunomodulation
FR2729380B1 (fr) Oxydes mixtes produits par voie pyrogenee, ayant des surfaces modifiees, procede pour leur preparation et utilisation
DE3380895D1 (de) Verfahren zur behandlung von eiern.
DE58903736D1 (de) Verfahren zur behandlung von biomassen, z.b. klaerschlaemmen, guelle, usw.
ATE552852T1 (de) Zusammensetzungen und verfahren zur behandlung von virusinfektionen
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
DE3584705D1 (de) Endotoxin von gram-negativ-bakterien blockierende monoklonale antikoerper, zellen die diese produzieren, zubereitungen die diese enthalten und verfahren zur herstellung dieser produkte.
DE3782214T2 (de) Mittel zur behandlung des scheidenmilieus.
DE58909850D1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
DE69114854T2 (de) Verfahren zur behandlung von photographischen abwässern.
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
DE3777656D1 (de) Mittel zur behandlung von alopezien.
DE3765137D1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von virus-infektionen.
DE69934057D1 (de) Verfahren zur Behandlung von Alkylamino (Meth)Acrylaten
DE990441T1 (de) Arzneimittel zur behandlung von diabetischer nephrosis
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.

Legal Events

Date Code Title Description
8332 No legal effect for de